Entero Therapeutics (NASDAQ:ENTO) Trading Up 5.2% – What’s Next?

Entero Therapeutics, Inc. (NASDAQ:ENTO) shot up 5.2% on Wednesday . The company traded as high as $5.03 and last traded at $4.69. Approximately 93,656 shares were traded during trading, a decline of 97% from the average session volume of 2,798,922 shares. The stock had previously closed at $4.46.

Entero Therapeutics Stock Performance

The firm has a market capitalization of $6.99 million, a PE ratio of -2.60 and a beta of 1.19. The company has a fifty day simple moving average of $4.32 and a two-hundred day simple moving average of $3.38.

Institutional Trading of Entero Therapeutics

A hedge fund recently bought a new position in Entero Therapeutics stock. Virtu Financial LLC bought a new position in shares of Entero Therapeutics, Inc. (NASDAQ:ENTO) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned approximately 0.74% of Entero Therapeutics at the end of the most recent reporting period. 12.30% of the stock is owned by institutional investors.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development.